Given the promising outcomes of immunotherapy, particularly immune checkpoint inhibitors such as PD‐1 and PD‐L1, in various malignancies including gastric cancer, we further explored the predictive potential of the risk score in the KIM and Hugo cohorts. This evidence concerns the gene PDCD1 and gastric cancer.